Roche sees high single-digit core profit growth in 2025
Roche said on Thursday it is targeting a continued increase in adjusted earnings per share (EPS) at a high single-digit percentage this year, helped by lower costs and growth from drugs such as eye treatment Vabysmo and cancer drug Phesgo. The goal, which is adjusted for currency swings, would mark continued earnings momentum as the Swiss drugs and diagnostics company said in its earnings statement that adjusted 2024 EPS gained 7%, also before foreign exchange effects. Total operating profit, adjusted for one-offs, came in at 20.8 billion Swiss francs ($23.0 billion) last year, just shy of average market expectations of about 21 billion francs.
